Menu

Menu

Menu

Learn More About FastWave and Our Proven Team with Deep Interventional Experience

All

Scott Nelson

Co-Founder and CEO

Tristan Tieso

COO

Sukanya Iyer

Head of Technology

Anindita Sengupta

Head of QA/RA

Trent Mengel

Head of Clinical

Lauren Fischer

Program Director

Curt Goreham-Voss, PhD

Principal Engineer

Julie Harrison

Systems Engineer

Andrew Waltz

Quality Engineer

Lisa Pritchard

Regulatory Advisor

Stephen Marks

Finance Lead

Josh Seidenfeld

Outside Counsel

Dan Rose

Strategic Advisor

Jim Palmer

Strategic Advisor

Brady Hatcher

Co-Founder and Director

JC Sun, PhD, MBA

Co-Founder and Director

Peter Schneider, MD

Vascular Surgeon

Art Lee, MD

Interventional Cardiologist

Amir Kaki, MD

Interventional Cardiologist

Farouc Jaffer, MD, PhD

Interventional Cardiologist

Miguel Montero-Baker, MD

Vascular Surgeon

Kathleen Kearney, MD

Interventional Cardiologist

Venkatesh Ramaiah, MD

Vascular Surgeon

Steven Kum, MD

Vascular Surgeon

Medical Advisors

Peter Schneider, MD

Vascular Surgeon

Art Lee, MD

Interventional Cardiologist

Amir Kaki, MD

Interventional Cardiologist

Farouc Jaffer, MD, PhD

Interventional Cardiologist

Miguel Montero-Baker, MD

Vascular Surgeon

Kathleen Kearney, MD

Interventional Cardiologist

Venkatesh Ramaiah, MD

Vascular Surgeon

Steven Kum, MD

Vascular Surgeon

Founders

Scott Nelson

Co-Founder and CEO

Brady Hatcher

Co-Founder and Director

JC Sun, PhD, MBA

Co-Founder and Director

Invest in the Future of IVL

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Invest in the Future of IVL

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Invest in the Future of IVL

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Invest in the Future of IVL

We oversubscribed our last round of financing in just a few weeks, so don’t miss out on the next opportunity to invest.

$40M+ raised from corporate venture, VC, and KOLs.

100% lesions crossed in successful first-in-human study.

Only market incumbent acquired in 2024 by J&J for $13B.

Follow FastWave's Journey

Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.

© 2025 FastWave Medical Inc.

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

Follow FastWave's Journey

Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.

© 2025 FastWave Medical Inc.

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

Follow FastWave's Journey

Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.

© 2025 FastWave Medical Inc.

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.

Follow FastWave's Journey

Next-level intravascular lithotripsy (IVL) devices for calcific artery disease.

© 2025 FastWave Medical Inc.

FastWave Medical is developing devices limited by Federal (or United States) law to investigational use. To see FastWave’s patents, click here.